Study on the Decontamination Effect of Eravacycline on Multidrug-Resistant Bacteria in Hypothermic Organ Preservation Solution

Abstract

Organ preservation solutions (PS) contaminated with multidrug-resistant bacteria (MDRB) risk donor-derived infections in transplantation. Eravacycline (ERV), a novel tetracycline antibiotic, shows potent activity against MDRB, but its efficacy in hypothermic PS (0°C–4°C) is unverified. In this study, six multidrug-resistant bacterial strains—including carbapenem-resistant Klebsiella pneumoniae, Acinetobacter baumannii, Escherichia coli, VIM-positive Pseudomonas aeruginosa, carbapenemase-negative P. aeruginosa, and methicillin-resistant Staphylococcus aureus—were exposed to eravacycline diluted in preservation solution at concentrations of 25, 50, 100, and 200 mg/L for three hours at 0–4°C. Bacterial viability was assessed by colony-forming unit counts after incubation. Results showed that eravacycline at 25 mg/L inhibited methicillin-resistant S. aureus and carbapenem-resistant A. baumannii, while 50 mg/L suppressed carbapenem-resistant K. pneumoniae, E. coli, and VIM-positive P. aeruginosa. Carbapenemase-negative P. aeruginosa required 200 mg/L for inhibition. These findings indicate that eravacycline exhibits strain-dependent antibacterial activity in hypothermic preservation solution, with 50 mg/L being effective against most tested multidrug-resistant organisms except carbapenemase-negative P. aeruginosa. Further clinical studies are warranted to evaluate its potential application in transplantation settings.